Segment Reporting

9 Months Ended

Sep. 30, 2018

Segment Reporting [Abstract]

Segment Reporting

Segment Reporting

In the first quarter of 2018, the Company announced a change to its internal structure to create two distinct business segments within Shire: a Rare Disease division and a Neuroscience division. The change was based on the Board's conclusion that the Neuroscience business warranted additional focus and investment and that there was a strong business rationale for creating the two divisions.

In the second quarter of 2018, the Company returned to a single segment approach to managing its business. This decision was precipitated by the Shire Board's acceptance of Takeda's offer to acquire the Company and reflects the Company’s focus on the performance of the entire business as it operates in this current environment. This step was taken to more closely align with how the financial information is viewed by the Executive Committee (Shire’s chief operating decision maker) for the purposes of making resource allocation decisions and assessing the performance of the business. Additionally, in the second quarter of 2018, the Company introduced a new product franchise called Established Brands to capture revenue for its non-promoted products that are facing or could face generic competition, such as LIALDA and PENTASA. Comparative financial information for 2017 was retrospectively restated herein.

In the periods set out below, U.S. and International Product sales by franchise were as follows:

	Three months ended
	September 30, 2018						September 30, 2017
(In millions)	U.S. Sales		International Sales		Total Sales		U.S. Sales		International Sales		Total Sales
Product sales by franchise
IMMUNOGLOBULIN THERAPIES	$	530.7	$	125.2	$	655.9	$	486.6	$	118.5	$	605.1
HEREDITARY ANGIOEDEMA	291.3		37.7		329.0		235.8		32.6		268.4
BIO THERAPEUTICS	91.9		120.4		212.3		86.3		110.3		196.6
Immunology	913.9		283.3		1,197.2		808.7		261.4		1,070.1
HEMOPHILIA	386.6		349.3		735.9		357.5		367.8		725.3
INHIBITOR THERAPIES	44.7		124.4		169.1		70.6		120.1		190.7
Hematology	431.3		473.7		905.0		428.1		487.9		916.0
VYVANSE	528.5		66.5		595.0		476.8		61.6		538.4
ADDERALL XR	71.5		4.8		76.3		99.4		6.6		106.0
MYDAYIS	19.3		—		19.3		10.2		—		10.2
Other Neuroscience(1)	0.9		40.2		41.1		6.7		29.8		36.5
Neuroscience	620.2		111.5		731.7		593.1		98.0		691.1
ELAPRASE	41.7		128.9		170.6		41.4		111.5		152.9
REPLAGAL	—		123.0		123.0		—		117.2		117.2
VPRIV	39.0		48.8		87.8		37.5		52.1		89.6
Genetic Diseases	80.7		300.7		381.4		78.9		280.8		359.7
LIALDA/MEZAVANT	88.9		30.2		119.1		61.4		25.3		86.7
PENTASA	65.7		—		65.7		72.1		—		72.1
Other Established Brands(2)	10.7		21.0		31.7		11.4		20.3		31.7
Established Brands	165.3		51.2		216.5		144.9		45.6		190.5
GATTEX/REVESTIVE	82.2		14.9		97.1		72.6		12.3		84.9
NATPARA/NATPAR	47.8		3.2		51.0		39.1		—		39.1
Other Internal Medicine(3)	0.1		28.9		29.0		0.6		35.9		36.5
Internal Medicine	130.1		47.0		177.1		112.3		48.2		160.5
Ophthalmics	92.1		1.3		93.4		77.4		—		77.4
Oncology (4)	33.4		17.1		50.5		47.2		21.3		68.5
Total product sales	$	2,467.0	$	1,285.8	$	3,752.8	$	2,290.6	$	1,243.2	$	3,533.8

⁽¹⁾ Other Neuroscience includes INTUNIV, EQUASYM, and BUCCOLAM.

⁽²⁾ Other Established Brands includes FOSRENOL and CARBATROL.

⁽³⁾ Other Internal Medicine includes AGRYLIN, PLENADREN, and RESOLOR.

⁽⁴⁾ Results include the Oncology franchise until the date of its sale on August 31, 2018.

In the periods set out below, Royalties and other revenues were as follows:

	Three months ended
(In millions)	September 30, 2018		September 30, 2017
Royalties	$	45.1	$	111.4
Other revenues	73.8		52.4
Royalties and other revenues	$	118.9	$	163.8

	Nine months ended
	September 30, 2018						September 30, 2017
(In millions)	U.S. Sales		International Sales		Total Sales		U.S. Sales		International Sales		Total Sales
Product sales by franchise
IMMUNOGLOBULIN THERAPIES	$	1,409.6	$	416.3	$	1,825.9	$	1,299.9	$	314.0	$	1,613.9
HEREDITARY ANGIOEDEMA	949.9		113.1		1,063.0		878.9		89.5		968.4
BIO THERAPEUTICS	254.8		328.9		583.7		231.9		314.8		546.7
Immunology	2,614.3		858.3		3,472.6		2,410.7		718.3		3,129.0
HEMOPHILIA	1,152.6		1,072.8		2,225.4		1,082.1		1,037.5		2,119.6
INHIBITOR THERAPIES	160.5		422.7		583.2		217.4		414.5		631.9
Hematology	1,313.1		1,495.5		2,808.6		1,299.5		1,452.0		2,751.5
VYVANSE	1,572.3		207.5		1,779.8		1,445.4		174.9		1,620.3
ADDERALL XR	219.4		12.7		232.1		225.9		16.4		242.3
MYDAYIS	40.4		—		40.4		25.9		—		25.9
Other Neuroscience(1)	6.0		111.8		117.8		13.5		77.8		91.3
Neuroscience	1,838.1		332.0		2,170.1		1,710.7		269.1		1,979.8
ELAPRASE	126.6		338.9		465.5		119.4		335.1		454.5
REPLAGAL	—		372.8		372.8		—		349.0		349.0
VPRIV	113.9		153.4		267.3		110.3		147.0		257.3
Genetic Diseases	240.5		865.1		1,105.6		229.7		831.1		1,060.8
LIALDA/MEZAVANT	194.8		92.2		287.0		402.0		67.6		469.6
PENTASA	215.6		—		215.6		224.5		—		224.5
Other Established Brands(2)	43.8		62.1		105.9		67.0		55.3		122.3
Established Brands	454.2		154.3		608.5		693.5		122.9		816.4
GATTEX/REVESTIVE	280.2		46.6		326.8		193.3		35.9		229.2
NATPARA/NATPAR	153.5		7.3		160.8		103.2		0.1		103.3
Other Internal Medicine(3)	0.8		100.5		101.3		1.3		103.9		105.2
Internal Medicine	434.5		154.4		588.9		297.8		139.9		437.7
Ophthalmics	252.9		2.9		255.8		173.4		—		173.4
Oncology (4)	124.8		63.6		188.4		135.3		54.0		189.3
Total product sales	$	7,272.4	$	3,926.1	$	11,198.5	$	6,950.6	$	3,587.3	$	10,537.9

⁽¹⁾ Other Neuroscience includes INTUNIV, EQUASYM, and BUCCOLAM.

⁽²⁾ Other Established Brands includes FOSRENOL and CARBATROL.

⁽³⁾ Other Internal Medicine includes AGRYLIN, PLENADREN, and RESOLOR.

⁽⁴⁾ Results include the Oncology franchise until the date of its sale on August 31, 2018.

In the periods set out below, Royalties and other revenues were as follows:

	Nine months ended
(In millions)	September 30, 2018		September 30, 2017
Royalties	$	175.4	$	329.7
Other revenues	183.0		148.1
Royalties and other revenues	$	358.4	$	477.8